Emmaus Life Sciences, Inc. (EMMA)
Stock Price:
$0.9000 USD
0.0000 (0.00%)
Updated Oct 26, 2020 11:57 AM EDT - Market closed
Key Info
| Market Cap |
43.62M |
| Revenue (ttm) |
7.46M |
| Net Income (ttm) |
-32.89M |
| Shares Out |
48.47M |
| EPS (ttm) |
-2.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$0.9000 |
| Previous Close |
$0.9000 |
| Change ($) |
0.0000 |
| Change (%) |
0.00% |
| Day's Open |
0.9700 |
| Day's Range |
0.9000 - 0.9700 |
| Day's Volume |
3,892 |
| 52-Week Range |
0.702 - 3.25 |
More Stats
| Market Cap |
43.62M |
| Enterprise Value |
26.20M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.47M |
| Float |
26.04M |
| EPS (basic) |
-4.34 |
| EPS (diluted) |
-2.09 |
| FCF / Share |
-0.15 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
41,217 |
| Short Ratio |
0.48 |
| Short % of Float |
0.16% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
5.85 |
| PB Ratio |
n/a |
| Revenue |
7.46M |
| Operating Income |
-11.89M |
| Net Income |
-32.89M |
| Free Cash Flow |
-6.88M |
| Net Cash |
17.42M |
| Net Cash / Share |
0.36 |
| Gross Margin |
59.39% |
| Operating Margin |
-159.45% |
| Profit Margin |
-441.10% |
| FCF Margin |
-92.24% |
| ROA |
-3.24% |
| ROE |
n/a |
| ROIC |
-116.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
24.0
Current: $0.9000
High
24.0
Target: 24.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 1.32 | 0.13 | 0.09 | 0.10 | 0.14 | 0.13 | 0.12 | 0.11 |
| Revenue Growth | 923.74% | 51% | -14.99% | -25.91% | 3.21% | 13.83% | 3.23% | - |
| Gross Profit | 0.49 | 0.08 | 0.08 | 0.10 | 0.06 | -0.01 | -0.02 | -0.04 |
| Operating Income | -10.24 | -7.10 | -3.77 | -2.65 | -3.82 | -4.20 | -4.81 | -5.29 |
| Net Income | -9.60 | -7.11 | -5.94 | -3.38 | -2.66 | -10.91 | -3.41 | -8.33 |
| Shares Outstanding | 0.87 | 0.47 | 0.11 | 0.08 | 0.08 | 0.06 | - | - |
| Earnings Per Share | -11.16 | -15.12 | -55.56 | -39.84 | -36.00 | -168.00 | -2,172.00 | -5,687.99 |
| Operating Cash Flow | -9.04 | -4.79 | -2.98 | -2.16 | -3.27 | -3.04 | -2.34 | -3.57 |
| Capital Expenditures | -0.06 | -0.13 | - | - | - | - | - | -0.02 |
| Free Cash Flow | -9.09 | -4.92 | -2.98 | -2.15 | -3.27 | -3.03 | -2.34 | -3.59 |
| Cash & Equivalents | 3.25 | 5.61 | 0.32 | 0.43 | 1.24 | 1.27 | 0.01 | 0.07 |
| Total Debt | 0.59 | 0.04 | 0.09 | 2.77 | 1.48 | 0.01 | 7.40 | 4.28 |
| Net Cash / Debt | 2.66 | 5.57 | 0.22 | -2.34 | -0.24 | 1.26 | -7.39 | -4.21 |
| Assets | 5.15 | 6.10 | 0.51 | 0.57 | 1.34 | 1.40 | 0.13 | 0.37 |
| Liabilities | 1.87 | 1.55 | 1.58 | 5.40 | 3.10 | 3.56 | 13.20 | 11.79 |
| Book Value | 4.02 | 4.55 | -1.06 | -4.84 | -1.76 | -2.16 | -13.07 | -11.42 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Emmaus Life Sciences, Inc. |
| Country |
United States |
| Employees |
28 |
| CEO |
Yutaka Niihara |
Stock Information
| Ticker Symbol |
EMMA |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: EMMA |
Description
Emmaus Life Sciences engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.